SOURCE: P2D Bioscience

P2D Bioscience

April 12, 2011 08:00 ET

P2D Bioscience Lead ADHD Drug Demonstrates Efficacy in Preclinical Testing

CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Apr 12, 2011) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of ADHD in preclinical ADHD models. The independently conducted studies were funded by a grant from the National Institutes of Health (NIH).

P2D Bioscience is developing PD2005, a proprietary dopamine transport inhibitor, for the treatment of ADHD. PD2005 is a psychostimulant like current first-line ADHD treatments amphetamine (Adderall® and Vyvanse®) and methylphenidate (Concerta®). In the present study, PD2005 was as effective in improving working memory, a core symptom of ADHD, as current first-line ADHD treatments in a preclinical study. Additionally, PD2005 was as effective as current first-line treatments in improving sustained attention, another core ADHD symptom, in a second preclinical study. The studies suggest that PD2005, amphetamine and methylphenidate demonstrate similar efficacy in treating ADHD.

The primary advantage of PD2005 over amphetamine and methylphenidate is PD2005's improved side effect profile.

"The primary criticism of current first-line ADHD treatments is their side effects," said Dr. Frank Zemlan, CEO of P2D. "The treatments are Schedule II drugs of abuse prescribed mainly to children. In contrast, a unique feature of P2D's lead ADHD compounds is that they demonstrate no abuse potential in the 'Gold Standard' of preclinical abuse liability testing."

Dr. Zemlan also indicated that the current ADHD market of over $3.5 billion (U.S.) is artificially constrained by side effects issues; most notably the reluctance of many parents to allow current first-line ADHD drugs with significant abuse and addiction potential to be administered to their children. P2D's ADHD drug development program focuses on this underserved group of parents and children.

Dr. Zemlan predicted, "A new ADHD drug without the side effect burden of current first line ADHD drugs will dominate the ADHD market."

About P2D Bioscience (P2D, Inc.)
P2D Bioscience is a privately-held biopharmaceutical company focused on developing treatments for central nervous system and pulmonary diseases. P2D is developing first-in-class treatments for these disorders using novel proprietary chemical compounds. For example, its ADHD dopamine transporters are tropane analogs structurally different from current first-line ADHD drug treatments, amphetamine and methylphenidate. Additional information about P2D products in development may be found at

Forward-Looking Statements

This press release contains forward looking-statements related to development of P2D's candidate drug products. Words such as, but not limited to, "believe," "could," "expect," "anticipate," "intend," "likely," "predict," "should,""suggest" and similar words identify forward-looking statements. These statements are not historical facts and are subject to risks and uncertainties that could cause actual results or the timing of specified events to differ materially from those set forth or implied herein including, without limitation, risks associated with preclinical and clinical development, regulatory approval, product commercialization, intellectual property claims and other risks related to P2D's activities.

Contact Information